Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319997 | 0.94 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL2326102 | 0.90 | OPRM1 (0.51) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL348764 | 0.83 | PGR (0.44) | — | |
| SCHEMBL10318609 | 0.81 | OPRM1 (0.60) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL24220122 | 0.80 | OPRM1 (0.76) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1510 | 0.80 | OPRM1 (0.58) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1769207 | 0.80 | OPRM1 (0.58) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL20780087 | 0.79 | OPRM1 (0.47) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL23225662 | 0.79 | OPRM1 (0.79) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Hydrochloric Acid SCHEMBL12273573 | 0.78 | OPRM1 (0.61) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1229034-B1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | PFIZER PROD INC (US) | 2005-04-13 | — | — | EP | disclosed |
| EP-1229034-B1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | PFIZER PROD INC (US) | 2005-04-13 | — | — | EP | disclosed |
| US-20040171798-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC | 2004-09-02 | — | — | US | disclosed |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-08-15 | — | — | US | disclosed |
| EP-1229034-A1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | Pfizer Products Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171798-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | NOX3, PDE4A, NOX1 | OPRM1 1911/4885OPRD1 1001/4885OPRK1 1064/4885 |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | NOX3, NOX1, NOX4 | OPRM1 1767/4885OPRD1 992/4885OPRK1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.